Barrx Medical set out seven years ago to compile enough clinical trial data to prove not only that ablation is a safe and effective way of treating Barrett's esophagus, but also that is cheaper than endoscopic surveillance. Its patience is beginning to pay off.
By Tom Salemi
Barrx Medical Inc. has done an effective job of navigating its HALO radiofrequency ablation device onto the commercial markets as a new treatment for Barrett's esophagus, a cellular change in the lining of the esophagus caused by chronic injury due to gastroesophageal reflux disease (GERD). Patients with Barrett's face a significantly higher risk for developing esophageal cancer
Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.
After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.
Rising Leader Jacob Rubens, who has co-founded and led several Flagship companies and is now origination partner, believes aspiring leaders should follow their bliss.
